Consultant Breast and Endocrine Surgeon.
The prognostic significance of the insulin-like growth factor-1 ligand and receptor expression in breast cancer tissue
Version of Record online: 7 APR 2011
Copyright © 2011 Wiley-Liss, Inc.
Journal of Surgical Oncology
Volume 104, Issue 3, pages 228–235, 1 September 2011
How to Cite
Chong, K. Y.M., Subramanian, A., Mokbel, K. and Sharma, A. K. (2011), The prognostic significance of the insulin-like growth factor-1 ligand and receptor expression in breast cancer tissue. J. Surg. Oncol., 104: 228–235. doi: 10.1002/jso.21916
- Issue online: 1 AUG 2011
- Version of Record online: 7 APR 2011
- Manuscript Accepted: 28 FEB 2011
- Manuscript Received: 10 JAN 2011
- risk biomarker;
- disease-free survival;
- adjacent normal breast tissue
Background and Objectives
Previous in vitro studies have suggested that IGF-1 stimulation can lead a more aggressive breast cancers and subsequent poor prognosis in breast cancer patients. We aim to how IGF-1 and IGF-1R mRNA levels in breast cancer are associated with disease-free survival (DFS) and other clinicopathological factors.
IGF-1 and IGF-1R mRNA levels were measured in breast cancer tissue from 132 patients using real-time PCR. DFS and clinicopathological information were obtained from patient case notes.
IGF-1 and IGF-1R mRNA levels did not correlate with any clinicopathological factors. Patients who relapsed had lower IGF-1 mRNA levels in their tumour tissue compared to those who remained disease-free during the 5-year follow-up period. Patients who had ER-positive breast cancers with high IGF-1 mRNA levels had longer DFS compared to those with low IGF-1 mRNA levels. IGF-1 mRNA levels was not associated with DFS in patients with ER-negative cancers. IGF-1R mRNA levels was not associated with DFS in any subgroup analysis. Multivariate analysis showed that IGF-1 mRNA levels and histopathological grade were independent predictors of DFS.
Breast cancer tissue IGF-1 expression is a favourable prognostic indicator and could be used in clinical setting in planning for adjuvant treatment. J. Surg. Oncol. 2011; 104:228–235. © 2011 Wiley-Liss, Inc.